In the first half of 2025, Russians purchased over 9.3 million packages of anti-anxiety medications worth 4.6 billion rubles. The anxiolytic market grew by 16.9% in monetary terms and 9.8% in physical volume compared to the same period last year. According to RNC Pharma analysts, 2024 showed similar dynamics, with a 17.3% increase in ruble sales and a 5.2% rise in packages.
One-third of the market (32.8%) is concentrated in four regions: Moscow, the Moscow Region, St. Petersburg, and Krasnodar Territory. The market in these regions continues to expand, with growth rates of 7-9% in packages and 13-18% in monetary terms. Conversely, the least consumption of anxiolytics occurs in the Nenets Autonomous Okrug, the Republic of Tuva, and Chukotka Autonomous District, where only 5,900 packages were sold during the period.
The analysts identified 31 trademarks from 26 manufacturers. The undisputed leader remains Afobazol, produced by the Russian pharmaceutical company Otis Pharma, which accounts for 45% of the market in both monetary and physical terms. However, its growth of 12% lagged behind the group’s average.
In second place is Grandaxin from the Hungarian firm Egis (part of the French Servier Group), which saw an 18% increase in sales over the year. Adaptol from Latvian company Olainfarm rounds out the top three. Notably, both Phenazepam from Russian manufacturer Valenta and Adaptol experienced minimal ruble dynamics, with physical volumes decreasing by 10% and 11%, respectively.
The highest growth was demonstrated by Stresam from French pharmaceutical company Biocodex, with a 54% increase in ruble sales over the year.
The top 10 anxiolytics also included Atarax (USB Pharma), Alprazolam (Organica), Selank (Peptogen), Tophizolam (Binnopharm and partners), and Spitomin (Servier).
Demand for antidepressants has been rising since March 2022. In early March of that year, sales reached 577,600 packages worth 525.6 million rubles— tripling in quantity and quadrupling in monetary value compared to the previous year.